A 52 year old woman presents to her physician for a check-up. She is recovering from a wrist fracture after a fall. Dual energy x-ray absorptiometry of the hip had shown her to have osteoporosis. She became menopausal at age 50 and did not begin hormone replacement therapy because of a strong family history of breast cancer. She now fears a future hip fracture and would like to begin a bone loss prevention regime.Which of the following pharmaceutical agents is most appropriate for this patient?
A 52 year old woman presents to her physician for a check-up. She is recovering from a wrist fracture after a fall. Dual energy x-ray absorptiometry of the hip had shown her to have osteoporosis. She became menopausal at age 50 and did not begin hormone replacement therapy because of a strong family history of breast cancer. She now fears a future hip fracture and would like to begin a bone loss prevention regime.Which of the following pharmaceutical agents is most appropriate for this patient?
💡 Explanation
**Core Concept**
The patient is at risk of future fractures due to osteoporosis, and the physician must choose an appropriate medication to prevent bone loss and reduce the risk of fractures. This scenario highlights the need for pharmacological interventions in the management of osteoporosis, particularly in postmenopausal women who are at increased risk of bone loss.
**Why the Correct Answer is Right**
Bisphosphonates, such as alendronate, work by inhibiting osteoclast-mediated bone resorption. They bind to hydroxyapatite in bone and are internalized by osteoclasts, leading to the inhibition of osteoclast activity and a reduction in bone resorption. This results in an increase in bone mineral density (BMD) and a reduction in the risk of fractures.
**Why Each Wrong Option is Incorrect**
**Option A:** Denosumab is a monoclonal antibody that inhibits RANKL, a protein that stimulates osteoclast formation and activation. While effective, it is not typically the first-line treatment for osteoporosis in postmenopausal women without other risk factors.
**Option B:** Teriparatide is a recombinant parathyroid hormone that stimulates bone formation by increasing osteoblast activity. It is typically reserved for patients with severe osteoporosis or those who have failed other treatments.
**Option C:** Raloxifene is a selective estrogen receptor modulator (SERM) that has estrogen agonist effects on bone and estrogen antagonist effects on breast and uterine tissue. It is not typically used as a first-line treatment for osteoporosis in postmenopausal women without other risk factors.
**Clinical Pearl / High-Yield Fact**
Bisphosphonates are generally well-tolerated, but long-term use can increase the risk of atypical femoral fractures and osteonecrosis of the jaw. Regular monitoring of renal function and dental health is essential in patients on bisphosphonate therapy.
**Correct Answer:** C. Raloxifene is not the best choice in this scenario. The best answer is actually **A. Denosumab.**
✓ Correct Answer: C. Raloxifene
📤 Share this MCQ
Share Card Preview
👆 1080x1080 square card — fills the full width in WhatsApp and Telegram